JERSEY CITY, N.J. — Mitsubishi Tanabe Pharma Corporation (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people...
Latest News
TORONTO – Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed through Prince Edward Island (PEI) Pharmacare under Special Authorization. “We want to thank the Government of Prince Edward Island for their leadership in making this treatment available to patients in...
Singapore – A group of researchers, led by Nanyang Technological University, Singapore (NTU Singapore), has developed a mobile application to educate individuals living with diabetes and their caregivers with knowledge of the disease and assist them in monitoring their day-to-day activities, which includes medication, physical activity, and their diet. The...
TOKYO & WALTHAM, Mass. – Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been published in the peer-reviewed journal Human Gene Therapy. The publication highlights compelling preclinical evidence that Modalis’ proprietary CRISPR-GNDM® epigenome editing technology can safely...
TOKYO, Japan & WALTHAM, Mass. — Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the preprint paper titled “Efficient and durable gene activation by Cas9-mediated epigenome editing in vivo”...
Gothenburg, Sweden – A moderate low-carbohydrate diet for adults with type 1 diabetes has advantages over traditional diet. The average blood sugar level is reduced and the time with good values during a 24 hour period is increased, without any negative health impact. This has been shown in a study...
Liam Little has a rare, life-threatening disease but even at his sickest, his mum Natasha says: “You couldn’t wipe the smile off his face.” The toddler, who has spent much of his life in hospital, was diagnosed with auto-immune enteropathy at nine months of age, a condition in which the...
CAMBRIDGE, MA / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational mRNA-based T-cell engager (TCE) for participants with relapsed or refractory multiple myeloma (RRMM). The first dose was administered at SCRI Oncology Partners in Nashville, Tennessee, in...
CAMBRIDGE, Mass. – Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory(CPI-R/R) melanoma patients will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025, in Berlin, Germany. mRNA-4359 is...
Moderna hopes to offer a new set of life-saving vaccines targeting cancer, heart disease and other conditions by 2030, a spokesperson for the company told CNBC on Monday. The spokesperson confirmed remarks Moderna’s chief medical officer, Dr. Paul Burton, made to the Guardian on Saturday. Burton said he’s confident those...